Sciensus

At Reuters Events Pharma 2025 in Barcelona, Alastair MacDonald delivered an insightful speaking session titled: “From data to profits: the goldmine pharma isn’t monetising… enough.” The session explored how Patient Support Programmes (PSPs) that integrate both digital tools and in-person nursing support can significantly improve patient engagement and adherence, driving better outcomes and long-term value. Alastair also addressed the untapped power of Patient-Reported Data (PRD) and how real-world patient experiences can generate valuable insights across market access, commercial, marketing, and medical affairs functions. If you missed our session, visit: https://lnkd.in/ebBY9y4W #ReutersPharma2025 #PatientSupportPrograms #PRD #Insights #LifeSciences

2 days to go until #ReutersPharma2025 Looking forward to learning from the brightest minds 🧠 in the pharmaceutical and healthcare industries on how we can shape a more innovative, patient-centric future. I’m especially interested in diving deeper into topics like real-world evidence and patient engagement, two areas I’m passionate about. If you’re attending and would like to chat further about these topics, feel free to DM me and we can set some time up to talk! #PharmaInnovation #HealthcareTransformation #RealWorldEvidence #PatientEngagement

Exciting News from the World Orphan Drug Congress USA! I am honored to be moderating a session at the World Orphan Drug Congress USA in Boston on April 22 from 1-2PM EST, titled "Breaking into Europe: Partnerships that Propel US Biotechs to Orphan Drug Success." One of our esteemed panelists is Kathy Senecal, a retired educator and the founder and Executive Director of the New England Chapter of the FSHD Society, who lives with Facioscapulohumeral muscular dystrophy (FSHD). I had the pleasure of meeting Kathy in Boston this past weekend, and I was thrilled to meet her and her lovely daughter. Both are strong advocates for the FSHD community. Their dedication and passion for raising awareness and supporting those impacted by FSHD are truly inspiring. I am grateful to be working for Sciensus, a company that not only values the patient voice but also incorporates it into our partnership solutions. It is a privilege to be part of an organization that prioritizes patient advocacy and strives to make a positive impact on the lives of those affected by rare diseases. Stay tuned for more updates from the World Orphan Drug Congress USA and join us in celebrating the incredible work being done to support the rare disease community! #WorldOrphanDrugCongress #RareDiseases #PatientAdvocacy #FSHD #Sciensus #Partnerships #Biotech

Key Strategies for Successful Orphan Drug Launch in Europe On March 28, I had the pleasure of co-moderating a recent XTalks webinar on the challenges and strategies for launching orphan drugs in Europe. The discussion was insightful and highlighted several key points. Polling Insights: During the webinar, we conducted several polls asking participants about the biggest challenges in launching orphan drugs in Europe. The results were telling: - 44% identified pricing and reimbursement as one of the biggest hurdles. - Another 44% pointed to market access complexities. - 11% mentioned regulatory hurdles. - 36% said tailored market access plans are critical for a successful launch. Expert Quotes: Kirstie Hoyle, CEO of Metabolic Support UK, emphasized the importance of patient association groups: "Patient organisations have access to communities, understand their conditions, and can share information that others can't. This proactive engagement is crucial for successful drug launches.” Andrew Cummins, Vice President and Business Development Lead at Sciensus, highlighted the need for strategic partnerships: "Think about your ambition and all the activities you need to do. Combining efforts under one partner rather than multiple (partners) can make the process smoother and more efficient.” The insights shared by our panellists were invaluable, and I look forward to applying these strategies to our work at Sciensus. #OrphanDrugs #Pharma #Healthcare #PatientCentricity #DrugLaunch #MarketAccess #Sciensus #Europe #XTalks

We are excited to announce that our experts, Alastair MacDonald, Raymond A. Huml, Andrew Cummins and Mathieu Loiseau, along with guest speakers Kathy Senecal and Grant Castor, will present at the World Orphan Drug Congress USA in Boston. Join us on April 22nd at 1:00 PM - 2:00 PM for our session, "Breaking into Europe: Partnerships That Propel U.S. Biotechs to Orphan Drug Success." This session will focus on: - Challenges U.S. biotechs face in Europe due to diverse languages, cultures, and regulations - Streamlining market entry - Navigating the European landscape - Overcoming barriers for successful drug launches - Enhancing market access through collaboration Looking to expand into European markets? Schedule a meeting with our team to learn how Sciensus can support your objectives: https://lnkd.in/ei73yy_J We look forward to connecting with you at the Congress. #WorldOrphanDrugCongress #RareDiseases #OrphanDrugs #MarketAccess #RealWorldEvidence #WODC

Real-world data (RWD) is rightfully recognised as a crucial tool in driving healthcare innovation and improving patient experience, provided it is used effectively. In our recent blog, Katie Duncalf, MSc explores some of the key ways in which RWD can inform healthcare strategies and decision-making to achieve a more patient-centred approach and improve outcomes. Discover how RWD is shaping the future of healthcare by visiting: https://lnkd.in/eSYrkxNn #RealWorldData #HealthOutcomes #PatientEngagement #Insights

We are proud to sponsor Reuters Pharma 2025 in Barcelona from 9th–11th April. Meet the team, Alastair MacDonald, Katie Duncalf, MSc, and Hiran Pandoria, and discover how to transform real-world patient insights into commercial impact. Don’t miss our speaking session on 9th April at 4:50 pm, where Alastair MacDonald, Vice President of Medical Affairs, will discuss: "From data to profits: the goldmine pharma isn’t monetising… enough." Want to learn more? Arrange a meeting with our team here: https://lnkd.in/eNcy7z82 #ReutersPharma #Pharma2025 #RealWorldInsights #Pharma #Insights #RealWorldData

Staying on track with cancer medication is critical, yet adherence rates for self-administered treatments remain low. Ensuring cancer patients adhere to their prescribed medication regimens is key for optimising treatment outcomes and reducing healthcare costs. While traditional ways of clinical practice might seem out-of-date, new technology offers promising solutions to the same age-old problems. Digital solutions like the Sciensus Cancer Companion app are transforming patient care with personalised reminders, real-time monitoring, and direct support. Find out more about revolutionising medication adherence in cancer care with digital solutions: https://lnkd.in/e2dZk5kx #OncologyCare #DigitalSolutions #PatientAdherence #CancerTreatment

Breaking into Europe: Partnerships That Propel US Biotechs to Orphan Drug Success As part of Sciensus, a leading European healthcare company committed to the rare disease community, I am excited to meet American sponsors of rare and orphan products who wish to market them in Europe. We provide European distribution solutions, expertise in Early Access Plans, real-world evidence (RWE), digital technologies for patient and caregiver reported outcomes, and Patient Support programs. On April 22, I will be moderating a workshop titled “Breaking into Europe: Partnerships That Propel US Biotechs to Orphan Drug Success” at the World Orphan Drug Congress 2025 at the Boston Convention & Exhibition Center in Boston. Panellists will include Andrew Cummins, Vice President of Rare Business Development; Alastair McDonald, Vice President of Medical Affairs; Mathieu Loiseau, Director of Clinical Operations; Grant Casto, Senior Vice President of Commercial Strategy and Operations at Sentynl Therapeutics; and Kathy Senecal, Retired Educator and Director of the New England Chapter of the Facioscapulohumeral Muscular Dystrophy (FSHD) Society. This session will discuss how EU partnerships can provide solutions for US companies seeking to market their rare disease treatments in Europe. If you or your organization wish to meet with us at the conference, please do not hesitate to reach out. We would be delighted to meet you! #RareDisease #OrphanDrugs #HealthcareInnovation #Biotech #Pharma #EuropeanMarket #PatientSupport #RWE #DigitalHealth #EarlyAccess #ClinicalOperations #MedicalAffairs #Sciensus #Partnerships #FSHD #PatientAdvocacyGroup

Launching an orphan drug in Europe has never been more challenging. The stakes are high. Stricter regulation. Tougher pricing negotiations. Growing influence from patient advocacy groups. The European market is more complex than ever and without the right strategy, delays, restricted access or commercial failure are real risks. Join our expert webinar to learn how to navigate market access, pricing and patient engagement in 2025. What you'll learn: - Why early patient engagement is critical for regulatory success and long-term adoption - The latest trends in European pricing and reimbursement and how to stay ahead - How collaborating with patient advocacy groups can unlock new market access opportunities If you're involved in orphan drug development, this is your chance to get practical, expert-backed strategies to accelerate access and maximise commercial success. Join Raymond A. Huml, Vice President of Rare Strategy at Sciensus, and Andrew Cummins, Vice President of Business Development at Sciensus, along with Kirsty Hoyle, CEO of Metabolic Support UK, on 28th March at 10am PDT / 1pm EDT / 5pm GMT. Register now: https://lnkd.in/eUyzcer8 #OrphanDrugs #MarketAccess #RegulatoryAffairs #PharmaStrategy #Biotech #RareDisease #LifeSciences Xtalks